Evelo Biosciences Inc

OTC Pink - Limited Information:EVLOUnited States

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.

Contact Information

Headquarters

124 WASHINGTON STREET, SUITE 101FOXBORO, MA, United States 02035

Phone

617-577-0300

Fax

302-655-5049

Executives

President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, Company Secretary, Director

Craig Jalbert

Chief Scientific Officer, President of Research and Development

Mark Bodmer

General Counsel, Secretary

Daniel Char

Chief Medical Officer

Duncan McHale

Chief Commercial Officer

Mark Plinio